Cargando…

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy. We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Jiliang, Xu, Hongwei, Zhang, Xiaoyan, Allamargot, Chantal, Coleman, Kristen L., Nessler, Randy, Frech, Ivana, Tricot, Guido, Zhan, Fenghuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405162/ https://www.ncbi.nlm.nih.gov/pubmed/28229908 http://dx.doi.org/10.1016/j.ebiom.2017.02.011

Ejemplares similares

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter
por: Violet, Pierre-Christian, et al.
Publicado: (2017)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
por: Bolaman, Ali Zahit, et al.
Publicado: (2021)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
por: Shi, Lei, et al.
Publicado: (2010)

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
por: Gu, Zhimin, et al.
Publicado: (2014)

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
por: Han, Seong-Su, et al.
Publicado: (2015)

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells
por: Schibler, Jeanine, et al.
Publicado: (2016)

Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells
por: Brandt, Kristin E., et al.
Publicado: (2017)

Epigenetic effects of pharmacologic ascorbate
por: Steers, Garett J., et al.
Publicado: (2021)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro
por: Noguera, Nélida I., et al.
Publicado: (2017)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Role of NEK2A in Human Cancer and Its Therapeutic Potentials
por: Xia, Jiliang, et al.
Publicado: (2015)

Hepatomas are exquisitely sensitive to pharmacologic ascorbate (P-AscH(-))
por: Zhang, Xuan, et al.
Publicado: (2019)

The role of mitochondria in pharmacological ascorbate-induced toxicity
por: Du, Juan, et al.
Publicado: (2022)

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients
por: Roy Choudhury, Samrat, et al.
Publicado: (2021)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
por: Hao, M, et al.
Publicado: (2017)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs
por: Musser, Margaret L., et al.
Publicado: (2019)

Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer
por: Steers, Garett J., et al.
Publicado: (2022)

Germline Risk Contribution to Genomic Instability in Multiple Myeloma
por: Janz, Siegfried, et al.
Publicado: (2019)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

The dual effect of pharmacological ascorbate on radiation: The best of both worlds
por: Cullen, Joseph J.
Publicado: (2018)

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2019)

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials
por: Gao, Minjie, et al.
Publicado: (2014)

Phenytoin Toxicity with High Dose, Concomitant Ascorbic Acid Dosing
por: Schuh, Michael J., et al.
Publicado: (2022)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Pharmacological Doses of Daily Ascorbate Protect Tumors from Radiation Damage after a Single Dose of Radiation in an Intracranial Mouse Glioma Model
por: Grasso, Carole, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_slgu843ll9509fohabflbtq2m4